Gracell Biotechnologies Inc expected to post a loss of 40 cents a share - Earnings Preview

Gracell Biotechnologies

11/08/2023 18:10

* Gracell Biotechnologies Inc  GRCL.OQ   GRCL.O  is expected
to show no change in quarterly revenue when it reports 
results on August 14. 
    * 
    * ​Refinitiv's mean analyst estimate for Gracell
Biotechnologies
Inc is for a loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $12​, above​ its last closing price
of $3.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.39       -0.39      -0.35     Beat    11.4
 Dec. 31 2023  -0.08       -0.21      -0.30     Missed  -45.6
 Sep. 30 2022  -0.18       -0.15      -0.35     Missed  -141​
 Jun. 30 2022  -0.07       -0.08      -0.30     Missed  -291.3
 ​​Mar.        -0.23       -0.21      -0.35     Missed  -66.7
 31 2022                                                
 Dec. 31 2021  -0.33       -0.33      -0.30     Beat    9.1​
 Sep. 30 2021  -0.15       -0.12      -0.30     Missed  -150
 Jun. 30 2021  -0.12       -0.12      -0.20     Missed  -71.4
 This summary was machine generated August 11 at 17:10 GMT.  All
figures in US dollars  unless otherwise stated